DOCSLIB.ORG

National Office for Drug Policy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
National Office for Drug Policy National Office for Drug Policy Use, abuse and trafficking of opioids in Mexico: The importance of international collaboration October, 2018 HIGH SPECIALIZATION IN DRUGS Collaborate with PHASE Production Routes Seizures Sampling Public policies Authorities Chemical and Crop Destruction of International Physical Strategic Specialized ACTIVITY Interception Focus actions Identification Crops Agencies Characterization Intelligence Program of substances Federal Level Pen Online PICS National Drug SPECIALIZED PRISM Observatory MEXW-34 AREA MEXK-54 National Control of COHESION Effort Synthetic Drugs SECURITY CABINET Monitoring System of Air and Maritime Traffic Prequim Impulse to integral improvement in Regulation of authorized List of Surveillance, Cooperation and production zones through the companies of controlled Use of statistical tools Early Warning System, coordination with promotion of actions oriented to the substances. to focus and prioritize consumption international agencies Sustainable Development of the Identify routes of illicit trafficking institutional efforts indicators and of substances to strengthen on drugs communities regulations PROMINENT surveillance in customs and ports State Level ACTIONS Internacional Global ONU Regional Grupos Binacionales STATISTICAL COORDINATION AMONG COORDINATION AND JUSTICE AND LAW ENFORCEMENT INTERNATIONAL PREVENTION SCOPE INDICATORS INSTITUTIONS INTEGRAL DRIVING DIMENSION Attention to Supply and Demand Comprehensive Policies and Strategies OVERVIEW GLOBAL OVERVIEW People worldwide used drugs at least once in 2016 Deaths indirectly attributable to 275 million drug Opioids implicated People who their drug use is 24% harmful to the point where they may need treatment Deaths associated with 31 million overdoses in Deaths related with drug use in 2015 2015 167, 750 450 000 76% It is estimated that in 2016, 34.3 million people used opioids and opiates for non-medical purposes Source: World Drug Report 2018 (United Nations publication, Sales No. E.18.XI.9). OPIOID USE IN MEXICO LEGAL FRAMEWORK International: Single Convention on Narcotic Drugs of 1961; Yellow List, List 1. National: General Health Law (LGS) Art. 234 (Narcotics). Its use is permitted for medical and scientific purposes LGS Art. 235; Medical Prescription (prescription) LGS Art.226, frac. I AGREEMENT: The compulsory nature of the comprehensive management of palliative care schemes is declared, as well as the processes indicated in the Guide. Source: National High Level Drug Policy Group. PHARMACEUTICAL OPIOIDS IN MEXICO Methadone Fentanyl LGS, Art.226, frac. I Morphine Codeine Hydromorphone Oxycodone Oxycodone / Paracetamol Sufentanil Remifentanyl The electronic special prescription is mandatory to get these narcotics for medical use. Source: National High Level Drug Policy Group. ABUSE OF PRESCRIPTION DRUGS IN MEXICO 1.3% of the population aged 12 to 65 has used medical drugs at some time (1.7% men, 0.9% women); 0.5% consumed them in the last year (0.6% men, 0.4% women). Consumption once: 406 235 Consumption once: 690 986 Consumption in the last year: 163 166 Consumption in the last year : 248 292 Medical drugs: Opiates, tranquilizers, sedatives, barbiturates or amphetamines, the use must be out of prescription or for a longer time or amount than indicated by the doctor. Source: National Survey ENCODAT 2016-2017. 2011: 178, 680 users 2016: 145, 382 users The downward trend is 18%. 0.2% of the population aged 12 to 65 has ever consumed 4, 812 140, 570 Source: National Survey ENCODAT 2016-2017. HEROIN SEIZURES RELATED WITH HEROIN Opium Poppy Erradication Clandestine Heroin Crops gum laboratories 1,015,904 Ui. 132,524.5 Has. 4,580.44 Kg. 23* 2,641.96 Kg. Poppy eradication hectares Source: Criminal Investigation Agency. National Effort. Preliminary figures HEROIN SEIZURES Source: Criminal Investigation Agency. National Effort. Preliminary figures HEROIN TRAFFICKING ROUTES TO THE UNITED STATES OF AMERICA WASHINGTON NUEVA YORK Illinois Connecticut COLORADO CALIFORNIA ARIZONA TEXAS GEORGIA D TERRAIN OPERATION Q AERIAL OPERATION HEROÍNA MÉXICO: DESTINO EEUU DESDE HEROÍNA EEUU: DESTINO EEUU DESDE MÉXICO MÉXICO December 1, 2012 to August 15, 2017 4 a 4 (2) 5 a 5 (1) 2 a 4 (1) 3 a 5 (3) NOTE: 3 natural ranges were considered (excluding zero). The natural ranges allow to generate 1 a 2 (9) 1 a 3 (5) ranges or intervals with values that are similar to each other but with significant difference with 0 a 0 (20) 0 a 0 (42) respect to the following range. The tip of the arrow indicates the direction of the route; the destination where heroin was seized. HEROÍNA Source: Criminal Investigation Agency. National Effort. Preliminary figures FENTANYL FENTANYL OVERVIEW 2017 Source: Criminal Investigation Agency. National Effort. Preliminary figures FENTANYL OVERVIEW 2018 Powder Tablets Ampoules (kg) (units) (units) 90 fentanyl related cases nationwide, since 2006. Source: Criminal Investigation Agency. National Effort. Preliminary figures EFFORTS OF THE MEXICAN GOVERNMENT SPECIAL PRESCRIPTIONS Paper Electronic Both forms in TRIPLICATE (Pharmacy, Patient, Doctor) Firma autógrafa del médico The electronic form can be generated through the website of the Ministry of Health. The electronic validation of the prescriptions through the alphanumeric reference of the two-dimensional code and the folio number, allow the validation by the pharmacies before being dispensed. Source:General Health Law. SPECIAL PRESCRIPTIONS Who can prescribe? Dispensing special prescriptions Medical surgeons SPECIAL PRESCRIPTIONS Medical Prescription (prescription) LGS Art.226, frac. I Dental surgeons • Medication for 30 days from prescription. • Validity of 30 days from the prescription. Veterinary doctors: • It is supplied and For use in animals retired. Source: National High Level Drug Policy Group. ACHIEVEMENTS OBJECTIVES OF REGULATING THE WHOLE SUPPLY CHAIN OF NARCOTICS AND PSYCHOTROPIC SUBSTANCES 1. Allow and promote use for therapeutic and scientific purposes. 2. Minimize the risk of abuse. 3. Reduce the risk of their illicit production, demand and traffic. Source: National High Level Drug Policy Group. LIMITED AVAILABILITY OF NARCOTICS AND PSYCOTROPIC SUSBSTANCES FOR MEDICAL AND SCIENTIFIC PURPOSES México´s average per capita consumption of morphine for 2013: 1.07 mg 54% lower than average 10 7.30 8 6 4.54 4.32 4.29 3.62 3.33 4 2.49 1.99 1.63 1.56 1.50 2 1.07 0.68 0.66 mg per capita por país 0.34 0.31 0.24 0.22 0.07 0.06 0.04 0.03 0 Source: International Narcotics Control Board; World Health Organization (2013). REGULATIONS PUBLISHED IN 2014 Became mandatory for all Health institutions to have operational and overall policy schemes for palliative care. COFEPRIS had to develop the operational guidelines for special prescription books for controlled substances. As a result, COFEPRIS created the electronic prescription books for opioids. COFEPRIS had to establish guidelines to facilitate the access and assure the supply of opioids. Source: Federal Comission for the Protection against Sanitary Risks (COFEPRIS) RESULTS IN ELECTRONIC PRESCRIPTION BOOKS Pain reduction and Palliative care Characteristics of Prescription Results* books Doctor data is protected 4,643 doctors with electronic prescription books Authorization via internet ( 300% increase). 200 prescriptions per application 1 day response. Prescription validation in pharmacies. Traceability of medicines. Source: National High Level Drug Policy Group. ACTIONS FOR DRUG CONTROL ILLICIT CROP MONITORING SYSTEM IN THE MEXICAN TERRITORY “MEXK54 PROGRAM” Objectives Technical capabilities Comprehensive public policies. Detection of illicit crops. Combat the supply and demand of drugs. 1 Sown area 2 Obtain Yield Kg/Ha statistical data on the planted 3 area where poppy and Chemical analysis marijuana are grown. Study of illicit crops through field work, to obtain the yield Generation Obtaining the of the same. Publication morphine of evidence- "Poppy Crop concentration Monitoring based 2014-2015". of the samples collected in the policies field. Source: MEXK54 Program Documento de uso cerrado ILLICIT CROP MONITORING SYSTEM IN THE MEXICAN TERRITORY “MEXK54 PROGRAM” For the period July 2014 - June 2015, the information was evaluated by the UNODC-Vienna to obtain the estimate of the area sown with poppy crops. Results 2014 - 20151 The results were published in June 2016 in Minimum Medium Maximum a national report and in Poppy sown Surface (Ha) 21,800 26,100 30,400 the 2016 World Drug Report. 2 For the period July 2015- Results 2015 - 2016 June 2016, the estimate of Minimum Medium Maximum poppy crops has been calculated. Poppy sown Surface (Ha) 20,400 25,200 30,000 Source: MEXK54 Project 1 Las cifras correspondientes a 2015 publicadas en la página 51 del Informe Mundial sobre las Drogas 2016 (publicación de las Naciones Unidas, número de venta: S. 16. XI. 7), se han revisado debido a un ajuste estadístico procesado por la UNODC. Estas Cifras corresponden al periodo de estimación de julio de 2014 a junio de 2015. Documento de uso cerrado https://www.unodc.ord/wdr2017/field/Booklet_2_HEALTH.pdf DRUG POLICIES BASED ON SCIENTIFIC EVIDENCE Procedure used to collect field data Source: MEXK54 Project 2. STRENGTHENING THE PROCESS OF COLLECTING DATA OF ERADICATION ACTIVITIES MEXW34 Data transmission via 3 satellite Compile Information in Institutional 2 Databases Generate file in 4 application (Information and 1 images) Monitor, collect and report information on erradication activities of illicit crops nationwide. Compile
Load more

Recommended publications
  • 2019 Ministerial Declaration
    COMMISSION ON NARCOTIC DRUGS VIENNA IMPLEMENTATION OF ALL INTERNATIONAL DRUG POLICY COMMITMENTS Follow-up to the 2019 Ministerial Declaration “Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem” UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Commission on Narcotic Drugs IMPLEMENTATION OF ALL INTERNATIONAL DRUG POLICY COMMITMENTS Follow-up to the 2019 Ministerial Declaration “Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem” UNITED NATIONS Vienna, 2019 © United Nations, July 2019. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Contents 1. Ministerial Declaration on Strengthening Our Actions at the National, Regional and International Levels to Accelerate the Implementation of Our Joint Commitments to Address and Counter the World Drug Problem ...............................1 2. Outcome document of the thirtieth special session of the General Assembly, entitled “Our joint commitment to effectively addressing and countering the world drug problem” ..................................................9 3. Joint Ministerial Statement of the 2014 High-Level Review by the Commission on Narcotic Drugs of the Implementation by Member States of the Political Declaration and Plan of Action on International Cooperation towards an Integrated and Balanced Strategy to Counter the World Drug Problem ...............................35 4.
    [Show full text]
  • Public Safety Aspects of the Heroin Abuse Epidemic
    A brief from June 2015 Public Safety Aspects of the Heroin Abuse Epidemic Overview Policymakers at all levels of government are attempting to address a nationwide increase in heroin abuse.1 Use of the drug has tripled over the past decade, paralleling widespread misuse of prescription opioids, and overdose deaths have increased nearly threefold in the past seven years. Available research suggests that the most effective response to the growth in heroin abuse is a combination of law enforcement to curtail trafficking and limit the emergence of new markets; alternative sentencing to divert nonviolent drug offenders from costly incarceration; treatment to reduce dependency and recidivism; and prevention efforts that can help identify individuals at high risk for addiction. These strategies are most effective when tailored to the specific nature of the heroin problem in a given community. Research further suggests that increasing criminal penalties for heroin-related offenses is unlikely to reverse the growth in heroin use and tends to have a poor return on investment. Figure 1 Heroin Seizures Increased Substantially Starting in 2007 Authorities cite expansion of Mexican production and trafficking 6,000 5,691 kg 5,000 4,000 3,000 2,486 kg 2,000 Heroin seizures (kilograms) 1,000 0 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 ‘13 Source: Office of National Drug Control Policy, 2014 National Drug Control Strategy, “Data Supplement, Table 71,” https://www. whitehouse.gov/sites/default/files/ondcp/policy-and-research/ndcs_data_supplement_2014.pdf © 2015 The Pew Charitable Trusts Heroin supply on the rise What Is Heroin? Between 2007 and 2013, heroin seizures by federal, state, and local law Heroin is a highly enforcement increased 289 percent.2 (See Figure 1.) U.S.
    [Show full text]
  • Diversion and Illicit Supply of Medicines
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Medicines Working Group Secretary: Mohammed Ali 1st Floor (NE), Peel Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 0459 Email: [email protected] Rt Hon. Amber Rudd MP Home Office 2 Marsham Street London SW1P 4DF Rt Hon. Jeremy Hunt MP Department of Health Richmond House 79 Whitehall London SW1A 2NS 15 December 2016 Dear Home Secretary and Secretary of State for Health ACMD report on Diversion and Illicit Supply of Medicines The Advisory Council on the Misuse of Drugs (ACMD) is pleased to enclose its report on Diversion and Illicit Supply of Medicines (referred to as ‘DISM’) for your consideration. This report is in response to the Home Office’s commissioning letter of September 2013, in which the then Home Secretary requested the ACMD to explore the potential for medical and social harms arising from the illicit supply of medicines – predominantly controlled medicines. We are grateful to the ACMD’s stakeholders, who provided presentations at the evidence gathering days as well as helpful written submissions (these are included in a separate attachment, alongside the main report on the ACMD website). This report sets out to: • explore the extent of DISM in the UK, to find out which drugs are being diverted; • evaluate the extent of the medical and social harms of such diversion; and • assess whether DISM displaces or replaces the use of known recreational drugs of abuse, such as heroin. In recent years, DISM has become of increasing public concern across the globe, although the hard evidence for this constituting a major problem other than in the United States is hard to find.
    [Show full text]
  • The Biden-Harris Administration's Statement of Drug Policy Priorities
    EXECUTIVE OFFICE OF THE PRESIDENT OFFICE OF NATIONAL DRUG CONTROL POLICY Washington, DC 20503 The Biden-Harris Administration’s Statement of Drug Policy Priorities for Year One The overdose and addiction crisis has taken a heartbreaking toll on far too many Americans and their families. Since 2015, overdose death numbers have risen 35 percent, reaching a historic high of 70,630 deaths in 2019.1 This is a greater rate of increase than for any other type of injury death in the United States.2 Though illicitly manufactured fentanyl and synthetic opioids other than methadone (SOOTM) have been the primary driver behind the increase, overdose deaths involving cocaine and other psychostimulants, like methamphetamine,3 have also risen in recent years, particularly in combination with SOOTM. New data suggest that COVID-19 has exacerbated the epidemic,4, 5 and increases in overdose mortality6 have underscored systemic inequities in our nation’s approach to criminal justice and prevention, treatment, and recovery. President Biden has made clear that addressing the overdose and addiction epidemic is an urgent priority for his administration. In March, the President signed into law the American Rescue Plan, which appropriated nearly $4 billion to enable the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration to expand access to vital behavioral health services. President Biden has also said that people should not be incarcerated for drug use but should be offered treatment instead. The President has also emphasized the need to eradicate racial, gender, and economic inequities that currently exist in the criminal justice system.
    [Show full text]
  • Rethinking America's Illegal Drug Policy
    NBER WORKING PAPER SERIES RETHINKING AMERICA'S ILLEGAL DRUG POLICY John J. Donohue III Benjamin Ewing David Peloquin Working Paper 16776 http://www.nber.org/papers/w16776 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 February 2011 The authors wish to thank Jonathan Caulkins, Phil Cook, Louis Kaplow, Rob MacCoun, Jeffrey Miron, Peter Reuter, and participants at two NBER conferences and the Harvard Law School Law and Economics workshop for valuable comments. We are also particularly grateful to Jeffrey Miron and Angela Dills for sharing their national time series data on drug prohibition enforcement and crime. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research. © 2011 by John J. Donohue III, Benjamin Ewing, and David Peloquin. All rights reserved. Short sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided that full credit, including © notice, is given to the source. Rethinking America's Illegal Drug Policy John J. Donohue III, Benjamin Ewing, and David Peloquin NBER Working Paper No. 16776 February 2011, Revised March 2011 JEL No. K0 ABSTRACT This paper provides a critical review of the empirical and theoretical literatures on illegal drug policy, including cross-country comparisons, in order to evaluate three drug policy regimes: criminalization, legalization and “depenalization.” Drawing on the experiences of various states, as well as countries such as Portugal and the Netherlands, the paper attempts to identify cost-minimizing policies for marijuana and cocaine by assessing the differing ways in which the various drug regimes would likely change the magnitude and composition of the social costs of each drug.
    [Show full text]
  • Five Proactive Steps Employers Can Take: Opioids in the Workplace
    Five Proactive Steps Employers Can Take: Opioids in the Workplace Opioids are powerful prescription pain relievers that can cause impairment, addiction, and fatal overdose. The United States is experiencing an opioid epidemic and Pennsylvania has been hit particularly hard. Opioid medications are both a health and a safety issue in the workplace. Fortunately, there are steps employers can take to keep their employees healthy and safe, and their companies productive. A Drug-Free Workplace in Five Steps Drug-free workplace programs are cost-effective plans that will help employers keep their employees safe and healthy. Effective programs should consist of these five components: 1. A Clear, Written Drug-free Workplace Policy The involvement of legal counsel and human resources is critical to ensure the policy includes protections for risk management, injury prevention, and liability. 2. Employee Education Make sure that employees receive information about how opioid medications could affect health, job performance, and safety. This includes: – Talking to doctors about non-opioid options for pain management – Avoiding driving and operating machinery while under the influence of drugs, including prescribed medications – Safe storage and disposal of medications – Not to share medications with family, friends, or colleagues – How to seek help for opioid addiction While illegal drugs used to be the focus, it is now important to offer frequent reminders of the prescription drug policy for your workplace. 3. Supervisor Training Supervisors are able to provide employee education regularly during individual and team meetings. Managers should have up-to-date knowledge on opioids and they must understand company drug policy. They should also have set steps to follow if they suspect problematic drug use.
    [Show full text]
  • STU-1002 – Alcohol, Tobacco and Other Drug Policy
    UNIVERSITY OF RICHMOND Policy Manual Policy #: STU-1002 Policy Title: Alcohol, Tobacco and Other Drug Policy Effective: 08/01/2021 Responsible Office: Compliance & Title IX Date Approval: Vice President for Student Development Approved: Replaces 07/01/2020 Responsible Deputy Title IX Coordinator for Students & Policy Dated: University Official: Substance Misuse Education and Prevention Coordinator PURPOSE: In accordance with the Drug Free Schools and Communities Act and its implementing regulations, the University of Richmond is required to communicate the following information regarding unlawful possession, use or distribution of alcohol, tobacco and illegal drugs to its students and employees. The purpose of this policy is to protect the health, safety and welfare of the members of the University community and the public served by the University. SCOPE: The Alcohol, Tobacco and Other Drug Policy applies to all students, staff, and faculty as well as third party users of University facilities. This policy applies to conduct that occurs on the campus of the University, on or in off-campus buildings or property of the University and at University sponsored activities, including off- campus education programs and activities and public property adjacent to the University. This policy also applies to University students studying abroad through a University approved study abroad program. INDEX: 1002.1................Policy & Rules 1002.2................Alcohol Policy 1002.3................Tobacco Policy University of Richmond | 1 STU-1002 – Alcohol, Tobacco and Other Drug Policy 1002.4 ….......... Marijuana Policy 1002.5................Drug Policy 1002.6................Sanctions for Alcohol, Tobacco and Other Drugs 1002.7................Federal and Commonwealth of Virginia Penalties 1002.8................Prevention and Education 1002.9................Health Risks 1002.10..............Resources POLICY STATEMENT: 1002.1 – Policy & Rules The University or Richmond strives to achieve a healthy living, learning and work environment.
    [Show full text]
  • Marijuana Policy Supplement
    Marijuana Policy Supplement June 2020 I. Introduction Marijuana, or cannabis, is the most commonly used illicit drug in the United States. Attitudes about its recreational and medicinal use have evolved significantly over the past 25 years, leading to legalization and decriminalization in a majority of states.1,2 The drug’s potential therapeutic and medicinal properties come from its multiple compounds, particularly delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD). An AHA scientific statement2 published in August 2020 critically reviews the medicinal and recreational use of cannabis from a clinical and public health perspective by evaluating its safety and efficacy profile, particularly in relationship to cardiovascular health. Key findings from this statement are summarized in Table 1. The consumption of cannabis products is increasing considerably, particularly among youth and young adults.2 Newer strains of marijuana are more potent, leading to risks including anxiety, agitation, hyperemesis syndrome, paranoia and psychosis.1 The U.S. Surgeon General has warned that recent increases in access to and potency of marijuana, along with misperceptions of the safety of marijuana, endanger youth, adolescents and the developing fetus.1 Under the 1970 Controlled Substances Act, marijuana is designated as a Schedule I drug with the highest level of control, a substance as having no safe medical use with a high risk of abuse or misuse. Schedule I substances are illegal under the law. However, as of May 2020, 33 states and Washington, D.C. have legalized marijuana for medical purposes, and 11 states and DC have legalized the drug recreationally, setting up a profound disconnect between state and federal law.
    [Show full text]
  • Drug Prohibition and Its Alternatives John J. Donohue III Stanford Law School and NBER February 2014
    Drug Prohibition and its Alternatives John J. Donohue III Stanford Law School and NBER February 2014 1. Introduction Illegal drugs, alcohol, and tobacco impose large social costs on society, here and in every major developed country. Interestingly, each of these is estimated -- albeit crudely -- to impose about $200 billion per year in social costs on the US (although the costs come in very different forms depending on the nature of the legal regime and enforcement policy). These three substances also share some interesting characteristics: many Americans have a serious attachment to one or more of them, and a sizeable proportion of the consumers use one or more of these in a responsible manner, hence imposing little-to-no external costs to society. The bad news is that a non-trivial subset also uses them irresponsibly, and this irresponsible use tends to create very high social costs. This problem is exacerbated by the fact that restricting use of drugs, alcohol, and tobacco to only those who impose minimal social costs is extremely difficult.1 Cocaine and opiates first became criminalized at the federal level in the United States in 1914, followed by marijuana in 1937. The criminalization of these drugs has led to the modern “war on drugs,” characterized by strict enforcement of drug violations and policing attempts directed at shutting down the drug trade. Scholars and policymakers, however, have questioned whether the “war on drugs” is really the optimal policy, with some suggesting that legalization and regulation may be a better alternative. A remarkable feature of this debate is that strong support exists for almost any position in the drug-policy debate.
    [Show full text]
  • Idpc Drug Policy Guide 3Rd Edition
    IDPC DRUG POLICY GUIDE 3RD EDITION IDPC Drug Policy Guide 3 IDPC DRUG POLICY GUIDE 3RD EDITION Acknowledgements Global Drug Policy Observatory) • Dave Borden (StoptheDrugWar.org) IDPC would like to thank the following authors for drafting chapters of the 3rd Edition of the • Eric Gutierrez (Christian Aid) IDPC Drug Policy Guide: • Fabienne Hariga (United Nations Office on • Andrea Huber (Policy Director, Penal Reform Drugs and Crime) International) • George McBride (Beckley Foundation) • Benoit Gomis (Independent international • Gloria Lai (IDPC) security analyst, Associate Fellow at Chatham House, and Research Associate at Simon Fraser • Graham Bartlett (former Chief Superintendent University) of the Sussex Police) • Christopher Hallam (Research Officer, IDPC) • Gregor Burkhart (European Monitoring Centre for Drugs and Drug Addiction) • Coletta Youngers (Consultant, IDPC & Washington Office on Latin America) • Ines Gimenez • Diana Guzmán (Associate investigator, • Jamie Bridge (IDPC) DeJusticia, Associate Professor at Colombian • Javier Sagredo (United Nations Development National University and PhD candidate at Program) Stanford University) • Jean-Felix Savary (Groupement Romand • Diederik Lohman (Associate Director, Health d’Etudes en Addictologie) and Human Rights Division, Human Rights • Juan Fernandez Ochoa (IDPC) Watch) • Katherine Pettus (International Association for • Gloria Lai (Senior Policy Officer, IDPC) Hospice and Palliative Care) • Jamie Bridge (Senior Policy and Operations Manager, IDPC) • Luciana Pol (Centro de Estudios
    [Show full text]
  • Pathways to Drug Policies That Work
    TAKING CONTROL: PATHWAYS TO DRUG POLICIES THAT WORK SEPTEMBER 2014 Apu Comes/Folhapress GLOBAL COMMISSION ON DRUG POLICY MEMBERS Kofi Annan Aleksander Kwasniewski chairman of the Kofi Annan Foundation and former former President of Poland Secretary-General of the United Nations, Ghana Ricardo Lagos Louise Arbour former President of Chile former UN High Commissioner for Human Rights, Canada George Papandreou CONTENTS former Prime Minister of Greece Pavel Bém Foreword from THE CHAIR 04 former mayor of Prague, Czech Republic Jorge Sampaio former President of Portugal EXECUTIVE Summary 06 Richard Branson entrepreneur, advocate for social causes, founder of the George Shultz THE ‘WAR ON DRUGS’ HAS FAILED Virgin Group, cofounder of The Elders, United Kingdom former Secretary of State, United States – NEW approaches ARE EMERGING 10 (honorary chair) Fernando Henrique Cardoso KEY pathways to drug POLICIES that work 16 former President of Brazil (chair) Javier Solana former European Union High Representative for the 2.1 Put people’s health and safety first 18 Maria Cattaui Common Foreign and Security Policy, Spain 2.2 Ensure access to essential medicines and pain control 20 former Secretary-General of the International 2.3 End the criminalization and incarceration of people who use drugs 21 Chamber of Commerce, Switzerland Thorvald Stoltenberg 2.4 Refocus enforcement responses to drug trafficking and organized crime 23 former Minister of Foreign Affairs and UN High Ruth Dreifuss Commissioner for Refugees, Norway 2.5 Regulate drug markets to put governments in control 26 former Minister of Social Affairs and former President of Switzerland Mario Vargas Llosa GLOBAL LEADERSHIP FOR MORE EFFECTIVE AND HUMANE POLICIES 32 writer and public intellectual, Peru Cesar Gaviria References and Notes 37 former President of Colombia Paul Volcker former Chairman of the US Federal Reserve and of the Annex.
    [Show full text]
  • Workplace Impacts of Marijuana Legalization
    Workplace Impacts of Marijuana Legalization This white paper has been reformatted and reprinted with permission fromassurexglobal.com ACE Private Risk Services® for the clients of Assurex Global Private Client Group members. 1 OVERVIEW In 2012, Colorado and Washington became the first states to legalize the recreational use and sale of marijuana. Since then, two other states and the District of Columbia have followed suit, while 18 others have legalized medical marijuana. Proponents tout the advantages of being able to regulate, tax and test marijuana. But what’s the impact on companies, particularly in relation to drug-free workplace policies? “As an employer’s lawyer, it seems to me that legalization of marijuana for recreational purposes is not a good thing,” says Paul L. Bittner, partner and vice chair of the Labor and Employment Group at Ice Miller. “I discourage employers from changing their drug-free workplace policies.” Bittner shared his thoughts on the workplace impact of marijuana legalization at an Assurex Global Loss Control & Claims meeting in September 2015. He began with a story about a client who called him last summer. The company in southeast Ohio was considering abandoning its pre-employment drug screening because it couldn’t recruit enough employees: Too many prospective employees tested positive for THC, the psychoactive chemical in marijuana. “That’s disturbing from an employer’s perspective,” says Bittner. “You don’t want people coming to work under the influence of a drug. You not only lose productivity, but the bigger concern for employers is potential liability if there’s an accident and someone gets hurt or killed.” Marijuana remains illegal under federal law.
    [Show full text]